ArticleNature cancer2022
METTL16 antagonizes MRE11-mediated DNA end resection and confers synthetic lethality to PARP inhibition in pancreatic ductal adenocarcinoma.
Abstract read
In one paragraph
Article in Nature cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed
7.7field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 66 citations in OpenAlex.
- BTAF1: a key regulator of DNA end resection and predictor of chemotherapy sensitivity in gastric cancer.Cell death and differentiation · 2026Article
- The MAZ-POLD1 Signaling Axis Drives Cisplatin Resistance in Bladder Cancer by Activating DNA Damage Repair.Cancers · 2026Article
- MRE11 Deficiency Occurs in a Small Group of Cancers from Various Different Tumor Entities.Diagnostics (Basel, Switzerland) · 2026Article
- DNA damage response signature-based prognostic genes for intrahepatic cholangiocarcinoma: a combined analysis of machine learning and biological experiments.Cancer cell international · 2026Article
- Interplay of RNA mFASEB bioAdvances · 2026Article
- Endothelial USP2a-METTL16 loop potentiates IL-6 signaling via mCell death and differentiation · 2026Article
- Article
- METTL16-mediated mJournal of experimental & clinical cancer research : CR · 2026Article
- METTL16 in cancer: Roles and regulatory mechanisms.Genes & diseases · 2026Review
- Redox-driven ADAR1 activation promotes Okazaki fragment maturation and DNA replication integrity.Nature structural & molecular biology · 2026Article
- MTUS2-AS1 suppression promotes DDX5 protein degradation to enhance the sensitivity of PARP inhibitors in BRCA-wild triple negative breast cancer.International journal of biological sciences · 2026Article
- The methyltransferase METTL16 in digestive system cancers: functions and mechanisms.Frontiers in oncology · 2026Review
- USP29 and SMURF1 orchestrate FSP1-mediated ferroptosis suppression to facilitate chemoresistance in gastric cancer.Nature communications · 2025Article
- ACOX2 destabilizes the MRE11-RAD50-NBS1 complex and boosts anticancer immunity via the cGAS-STING pathway in clear cell renal cell carcinoma.Molecular cancer · 2025Article
- Article
- METTL16-dependent GPX4 mBMC cancer · 2025Article
- Mechanisms and regulation of DNA end resection in the maintenance of genome stability.Nature reviews. Molecular cell biology · 2025Review
- The catalytic efficiency of METTL16 affects cellular processes by governing the intracellular S-adenosylmethionine setpoint.Cell reports · 2025Article
- Targeting MTAP increases PARP inhibitor susceptibility in triple-negative breast cancer through a feed-forward loop.The Journal of clinical investigation · 2025Article
- The dual role of RNA-binding proteins: promotion of tumorigenesis, drug resistance, and emerging therapeutic targets.Acta biochimica et biophysica Sinica · 2025Article
Corrections and comments
- Commented on by
Authors and funding
32 authors at 12 institutions in 3 countries.
Xiangyu Zeng *Department of Gastrointestinal Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.ORCID http://orcid.org/0000-0003-4913-3704
Fei Zhao *Department of Oncology, Mayo Clinic, Rochester, MN, USA.
Gaofeng CuiDepartment of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN, USA.
Yong ZhangDepartment of Radiation Oncology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Rajashree A DeshpandeDepartment of Molecular Biosciences, University of Texas at Austin, Austin, TX, USA.
Yuping ChenKey Laboratory of Arrhythmias of the Ministry of Education of China, Research Center for Translational Medicine, East Hospital, Tongji University School of Medicine, Shanghai, China.ORCID http://orcid.org/0000-0001-8562-0804
Min DengDepartment of Oncology, Mayo Clinic, Rochester, MN, USA.
Jake A KloeberDepartment of Oncology, Mayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0002-6646-564X
Yu ShiDepartment of Oncology, Mayo Clinic, Rochester, MN, USA.
Qin ZhouDepartment of Oncology, Mayo Clinic, Rochester, MN, USA.
Chao ZhangDepartment of Oncology, Mayo Clinic, Rochester, MN, USA.
Jing HouDepartment of Oncology, Mayo Clinic, Rochester, MN, USA.
Wootae KimSoonchunhyang Institute of Med-bio Science (SIMS), Soonchunhyang University, Cheonan-si, Republic of Korea.ORCID http://orcid.org/0000-0003-4364-3260
Xinyi TuDepartment of Oncology, Mayo Clinic, Rochester, MN, USA.
Yuanliang YanDepartment of Oncology, Mayo Clinic, Rochester, MN, USA.
Zhijie XuDepartment of Oncology, Mayo Clinic, Rochester, MN, USA.
Lifeng ChenDepartment of Oncology, Mayo Clinic, Rochester, MN, USA.
Huanyao GaoDepartment of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0002-9441-9579
Guijie GuoDepartment of Oncology, Mayo Clinic, Rochester, MN, USA.
Jiaqi LiuDepartment of Oncology, Mayo Clinic, Rochester, MN, USA.
Qian ZhuDepartment of Oncology, Mayo Clinic, Rochester, MN, USA.
Yueyu CaoKey Laboratory of Arrhythmias of the Ministry of Education of China, Research Center for Translational Medicine, East Hospital, Tongji University School of Medicine, Shanghai, China.
Jinzhou HuangDepartment of Oncology, Mayo Clinic, Rochester, MN, USA.
Zheming WuDepartment of Oncology, Mayo Clinic, Rochester, MN, USA.
Shouhai ZhuDepartment of Oncology, Mayo Clinic, Rochester, MN, USA.
Ping YinDepartment of Oncology, Mayo Clinic, Rochester, MN, USA.
Kuntian LuoDepartment of Oncology, Mayo Clinic, Rochester, MN, USA.
Georges MerDepartment of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0002-1900-1578
Tanya T PaullDepartment of Molecular Biosciences, University of Texas at Austin, Austin, TX, USA.
Jian YuanKey Laboratory of Arrhythmias of the Ministry of Education of China, Research Center for Translational Medicine, East Hospital, Tongji University School of Medicine, Shanghai, China. yuanjian229@hotmail.com.ORCID http://orcid.org/0000-0002-2801-8849
Kaixiong TaoDepartment of Gastrointestinal Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. kaixiongtao@hust.edu.cn.ORCID http://orcid.org/0000-0002-7723-6121
Zhenkun LouDepartment of Oncology, Mayo Clinic, Rochester, MN, USA. lou.zhenkun@mayo.edu.ORCID http://orcid.org/0000-0003-1938-3091
Mayo Clinic in Arizona · USTongji University · CNCentral South University · CNMayo Clinic · USThe University of Texas at Austin · USUnion Hospital · CNBeijing Institute of Education · CNChinese Academy of Medical Sciences & Peking Union Medical College · CNFirst Affiliated Hospital of Xi'an Jiaotong University · CNHubei Cancer Hospital · CNRuijin Hospital · CNSoonchunhyang University · KR
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers. Characterization of genetic alterations will improve our understanding and therapies for this disease. Here, we report that PDAC with elevated expression of METTL16, one of the 'writers' of RNA N
Indexed as
Carcinoma, Pancreatic DuctalMethyltransferasesMRE11 Homologue ProteinPancreatic NeoplasmsAdenosine Diphosphate RiboseDNAExonucleasesHumansPoly(ADP-ribose) Polymerase InhibitorsPoly(ADP-ribose) PolymerasesRNASynthetic Lethal MutationsAdenosine Diphosphate RiboseDNAExonucleasesMethyltransferasesMETTL16 protein, humanMRE11 Homologue ProteinMRE11 protein, humanPoly(ADP-ribose) Polymerase InhibitorsPoly(ADP-ribose) PolymerasesRNA
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.